FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213442860> ?p ?o ?g. }

• W3213442860 endingPage "A898" @default.
• W3213442860 startingPage "A898" @default.
• W3213442860 abstract "Background Regulatory T cells (Tregs) inhibit immune responses in solid cancers using cell-cell contacts and anti-inflammatory cytokine release. Also, due to high and constitutive levels of IL2Ralpha chain (CD25) expression, Tumor infiltrating (TIL)-Tregs cells preferably consume local Interleukin-2 (IL2), thus depriving conventional T cells from IL2-induced activation and proliferation. Therefore, the selective depletion of TIL-Tregs using therapeutic antibodies targeting CD25 represents a promising strategy to unleash tumor-specific immune responses in solid cancers. Methods CD25 expression was evaluated by flow and mass cytometry on T -cell subsets from tumor biopsies collected in patients with various solid cancers (Breast, Endometrial and Cervix). ALD2510 potency was demonstrated in vitro and in vivo in human CD25 Knock-In huGEMM (huCD25-KI) MC38-bearing mice and in CD34+ humanized NSG mice grafted with human cancer cell lines (MDA-MB-231 and HT29). Results In tumor biopsies, CD25 is highly and homogeneously expressed by TIL-Tregs, while being much less expressed by only a fraction of conventional CD4+ T cells and barely expressed by TIL-CD8+ cells. This confirms CD25 as the most selective marker to target TIL-Tregs in cancer patients.In vitro, ALD2510 shows potent ADCC and ADCP as well as strong Treg depletion capacity. Importantly, CD8+ and CD4+ conventional T cells are not impacted by ALD2510 even after activation confirming ALD2510 ability to selectively deplete Tregs. Accordingly, ALD2510 neither blocks IL-2 binding to CD25 nor inhibits IL-2 induced proliferation of activated T cells. In CD34+-humanized mice, ALD2510 efficiently depletes human Tregs but spares conventional T cells. Also, in the MC38 model in huCD25-KI mice, ALD2510 shows a strong anti-tumor activity as a single agent with 60% overall tumor growth inhibition together with massive Treg depletion 7 days after a single administration. In addition, combination of ALD2510 with anti-PD1 leads to complete tumor regression and strong activation of conventional T cells. Importantly, Basiliximab, a CD25-specific IL-2 blocking antibody, although efficient at depleting Treg cells, did not impact tumor growth, thus demonstrating that the IL-2 sparing feature of ALD2510 is critical to elicit anti-tumour response in vivo. Conclusions This preclinical data package supports CD25 as a potent and selective Treg marker allowing Tregs depletion while sparing conventional T cells. In this context, ALD2510, a novel humanized CD25-specific and IL-2 sparing antibody presents all the required attributes for selective and efficient TIL-Tregs depletion, making it a promising drug candidate to treat a broad range of solid tumor patients. Ethics Approval The studies involving human material were approved by the ethical committee “Comité de Protection des Personnes Sud Méditerranée » under approval numbers 1362 and 1048. All participants gave informed consent before taking part." @default.
• W3213442860 created "2021-11-22" @default.
• W3213442860 creator A5012827149 @default.
• W3213442860 creator A5025537277 @default.
• W3213442860 creator A5029679351 @default.
• W3213442860 creator A5030300591 @default.
• W3213442860 creator A5040446667 @default.
• W3213442860 creator A5044484762 @default.
• W3213442860 creator A5061305607 @default.
• W3213442860 creator A5061551018 @default.
• W3213442860 creator A5072226202 @default.
• W3213442860 creator A5079113367 @default.
• W3213442860 creator A5082206616 @default.
• W3213442860 date "2021-11-01" @default.
• W3213442860 modified "2023-09-30" @default.
• W3213442860 title "857 Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody" @default.
• W3213442860 doi "https://doi.org/10.1136/jitc-2021-sitc2021.857" @default.
• W3213442860 hasPublicationYear "2021" @default.
• W3213442860 type Work @default.
• W3213442860 sameAs 3213442860 @default.
• W3213442860 citedByCount "3" @default.
• W3213442860 countsByYear W32134428602022 @default.
• W3213442860 countsByYear W32134428602023 @default.
• W3213442860 crossrefType "journal-article" @default.
• W3213442860 hasAuthorship W3213442860A5012827149 @default.
• W3213442860 hasAuthorship W3213442860A5025537277 @default.
• W3213442860 hasAuthorship W3213442860A5029679351 @default.
• W3213442860 hasAuthorship W3213442860A5030300591 @default.
• W3213442860 hasAuthorship W3213442860A5040446667 @default.
• W3213442860 hasAuthorship W3213442860A5044484762 @default.
• W3213442860 hasAuthorship W3213442860A5061305607 @default.
• W3213442860 hasAuthorship W3213442860A5061551018 @default.
• W3213442860 hasAuthorship W3213442860A5072226202 @default.
• W3213442860 hasAuthorship W3213442860A5079113367 @default.
• W3213442860 hasAuthorship W3213442860A5082206616 @default.
• W3213442860 hasBestOaLocation W32134428601 @default.
• W3213442860 hasConcept C167672396 @default.
• W3213442860 hasConcept C203014093 @default.
• W3213442860 hasConcept C2776090121 @default.
• W3213442860 hasConcept C2776156784 @default.
• W3213442860 hasConcept C2778326572 @default.
• W3213442860 hasConcept C2778690821 @default.
• W3213442860 hasConcept C502942594 @default.
• W3213442860 hasConcept C553184892 @default.
• W3213442860 hasConcept C79484868 @default.
• W3213442860 hasConcept C86803240 @default.
• W3213442860 hasConcept C8891405 @default.
• W3213442860 hasConceptScore W3213442860C167672396 @default.
• W3213442860 hasConceptScore W3213442860C203014093 @default.
• W3213442860 hasConceptScore W3213442860C2776090121 @default.
• W3213442860 hasConceptScore W3213442860C2776156784 @default.
• W3213442860 hasConceptScore W3213442860C2778326572 @default.
• W3213442860 hasConceptScore W3213442860C2778690821 @default.
• W3213442860 hasConceptScore W3213442860C502942594 @default.
• W3213442860 hasConceptScore W3213442860C553184892 @default.
• W3213442860 hasConceptScore W3213442860C79484868 @default.
• W3213442860 hasConceptScore W3213442860C86803240 @default.
• W3213442860 hasConceptScore W3213442860C8891405 @default.
• W3213442860 hasIssue "Suppl 2" @default.
• W3213442860 hasLocation W32134428601 @default.
• W3213442860 hasLocation W32134428602 @default.
• W3213442860 hasOpenAccess W3213442860 @default.
• W3213442860 hasPrimaryLocation W32134428601 @default.
• W3213442860 hasRelatedWork W181678093 @default.
• W3213442860 hasRelatedWork W2005666125 @default.
• W3213442860 hasRelatedWork W2020684972 @default.
• W3213442860 hasRelatedWork W2047209980 @default.
• W3213442860 hasRelatedWork W2355095363 @default.
• W3213442860 hasRelatedWork W2464386733 @default.
• W3213442860 hasRelatedWork W3031438654 @default.
• W3213442860 hasRelatedWork W3138050922 @default.
• W3213442860 hasRelatedWork W2185732136 @default.
• W3213442860 hasRelatedWork W2396811992 @default.
• W3213442860 hasVolume "9" @default.
• W3213442860 isParatext "false" @default.
• W3213442860 isRetracted "false" @default.
• W3213442860 magId "3213442860" @default.
• W3213442860 workType "article" @default.